Andrea Corbacioglu

University Hospital Ulm — Germany

Medicine · Health Sciences

16h-index5.0kcitations51works7.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(51), Myeloproliferative Neoplasms: Diagnosis and Treatment(20), Chronic Myeloid Leukemia Treatments(13), Protein Degradation and Inhibitors(12), Acute Lymphoblastic Leukemia research(6)

Publications51 total

Measurable residual disease monitoring in AML with <i>FLT3</i>-ITD treated with intensive chemotherapy plus midostaurin
Blood Advances·2024· 10 citedOpen Access
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
HemaSphere·2024· 4 citedOpen Access
The Genomic Landscape and Its Clinical Implication in <i>NPM1</i>-Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial
Blood·2023· 3 cited
S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
HemaSphere·2023· 4 citedOpen Access
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
Blood Advances·2020· 67 citedOpen Access
Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with <i>FLT3</i> Internal Tandem Duplication (<i>FLT3</i>-ITD+ AML) Treated with Additional Midostaurin
Blood·2020· 3 citedOpen Access
Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Blood·2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i>-mutated AML: results from the AMLSG 09-09 trial
Blood·2020· 115 citedOpen Access
Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)
Blood·2019· 1 cited
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Blood·2019· 110 citedOpen Access
Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
Leukemia·2019· 5 citedOpen Access
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Nature Communications·2019· 120 citedOpen Access
Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)
Blood·2018
Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)
Blood·2016· 10 cited
Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG)
Blood·2015· 1 cited
Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Blood·2015· 1 cited
Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)
Blood·2015· 1 cited
Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)
Blood·2015· 5 cited
Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)
Blood·2015· 1 cited
Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML)
Blood·2015
page 1 of 3Next →

Frequent Co-authors

Konstanze Döhner(50), Hartmut Döhner(48), Richard F. Schlenk(43), Arnold Ganser(40), Lars Bullinger(39), Verena I. Gaidzik(33), Peter Paschka(27), Jürgen Krauter(22), Michael Heuser(20), Felicitas Thol(19), Katharina S. Götze(18), Daniela Weber(16), Stefan Fröhling(15), Frank G. Rücker(15), Michael Lübbert(15), Thomas Kindler(14), Walter Fiedler(14), Daniela Späth(13), Brigitte Schlegelberger(13), Nikolaus Jahn(12)